Could respiratory allergy reduce COVID-19 risk? {#sec1}
===============================================

SARS-CoV-2 has led to the COVID-19 global pandemic. Respiratory allergy and allergic asthma have not been identified as significant risk factors for COVID-19 despite their well-known association with more severe respiratory viral illnesses. Angiotensin-converting-enzyme 2 (ACE2) is the receptor for SARS-CoV-2 infections. Jackson et al (p 203), in this Letter to the Editor, aimed to determine whether respiratory allergy, allergic asthma, and/or controlled allergen exposure were associated with reductions in *ACE2* gene expression, hypothesizing that this could reduce risk of COVID-19. The authors found that:•Nasal epithelium *ACE2* expression was significantly lower in children with allergic sensitization.•Children with asthma and high levels of allergic sensitization had the lowest *ACE2* expression (see Figure) while patients with non-atopic asthma had highest level.•There was an inverse relationship between IgE level and ACE2 expression.•Allergen challenge led to significant reductions in *ACE2* expression in the upper and lower airways.

These studies suggest that patients with allergic inflammation (probably mediated by T~H~2 cytokines) might fare better than patients with an underlying inflammatory cytokine profile. Further studies are needed to define the role of respiratory allergy and type 2 inflammation in COVID-19 infection and illness severity.ACE2 expression is lower in the nasal epithelium of children with allergic sensitization and atopic asthma.

Longitudinal hematologic and immunologic variations associate with the prognosis of COVID-19 {#sec2}
============================================================================================

Previous cross-sectional studies had retrospectively analyzed relationships between clinical characteristics, laboratory findings, and severity of outcomes in patients with COVID-19. However, the dynamic changes of hematologic and immunologic indices and their associations with the prognosis of the disease remain largely unclear. Via a longitudinal analysis in this issue, Chen et al (p 89) revealed the following:•Low numbers of lymphocytes (T cells in particular) and eosinophils were associated with increased disease severity upon admission.•During hospitalization, eosinophils, platelets and lymphocytes showed an increasing trend in survivors but maintained lower levels or dropped even further in non-survivors.•Non-survivors kept a high level or an upward trend for neutrophils, IL-6, procalcitonin, D-Dimer, amyloid A protein and C-reactive protein while these levels were stable or trended downward in survivors.

These findings suggest that attention should be paid to dynamic changes of laboratory indices during hospitalization in order to determine survival trends.Graphical abstract.

Does maternal SARS-CoV-2 infection affect the immunologic status of newborns? {#sec3}
=============================================================================

The incidence and mortality rate of critical illness among the elderly and those with underlying immunosuppression are relatively high. The immaturity of immunologic function in children and newborns leads to their increased susceptibility to viral infections, while the immaturity of adaptive immunologic development may make their clinical symptoms different from those in adults. Together, these aspects raise questions as to why clinical manifestations of infected children and newborns are different from those of of elderly or immunosuppressed adults and pose the question as to the impact of maternal infection on the immunologic function of the fetus. In this issue, Liu et al (p 101) analyzed the immunologic status of newborns born to mothers with COVID-19 in the third trimester. Findings from the study included:•Under strict protective measures, 51 newborns born to SARS-CoV-2 infected mothers in the third trimester were not infected with SARS-CoV-2.•Mother\'s infection had no significant effect on the cellular and humoral immunologic status of the newborn, and lymphocyte differentiation was not affected significantly.•Third trimester pregnant women with mild to moderate COVID-19 gave birth to healthy babies.

The results from this research may further help us understand the immune function of newborns delivered by mothers infected with SARS-CoV-2 and improve treatment and prevention strategies.Chest radiographs were performed on the day, or the next day, of admission, which showed no pneumonia changes. **A,** The chest CT examination of 1 case with 2 consecutive suspected positive results of pharyngeal swab nucleic acid after birth. **B,** Chest x-ray picture of neonate born to SARS-CoV-2 infected mother.

Type-I IFN deficiency in severe COVID-19 patients {#sec4}
=================================================

Type I interferons (IFN-I) are major components of the innate immune system and represent critical antiviral molecules, of particular interest during the outbreak of coronavirus disease 2019 (COVID-19). In this issue, Trouillet-Assant et al (p 206) have investigated the kinetics of plasma IFN-I using digital ELISA (SIMoA) in COVID-19 critically ill patients. The authors reported the following:•Most COVID-19 patients demonstrated a peak in plasma IFN-α2 concentration at day 8-10 following symptoms onset, corresponding to the viral replication phase.•About 20% of patients presented with sustained abrogation of IFN-I production; this was associated with a poor outcome.•All patients showed a strong inflammatory response (CRP, IL-6, or IP-10), which started early and remained high while IFN-I response decreased after day 10 of infection.

Taken together, the heterogeneous pattern of IFN-α response in COVID-19 patients suggests that early intervention with recombinant IFN-α2 might be worth investigating for COVID-19 treatment.Plasma IFN-α2, IL-6, CRP, and IP-10 concentrations in COVID-19 critically ill patient cohort (n = 26). **A**, Plasma IFN-α concentrations (fg/mL) were determined by single-molecule array (Simoa). Fit Loess curve represents local polynomial regression performed with Loess method. CI at 95% was indicated (*orange area*). **B-D**, CRP (μg/mL), IL-6, and IP-10 (pg/mL) concentrations were measured using a multiplexed assay with the Ella platform. Normal values for healthy volunteers were indicated by *grey area*. *Vertical bar* indicates the median delay between symptom onset and intensive care unit admission

COVID-19 receptor (ACE2) expression in the airways of people with asthma {#sec5}
========================================================================

Whether asthma biology or treatment with inhaled corticosteroids are risk factors for severe COVID-19 disease is unknown. Bradding et al (p 208) explored ACE2 receptor mRNA expression, and co-factors for Sars-CoV-2 infectivity (TMPRSS2 and furin) in bronchial epithelial brushes and tissue biopsies from 268 people with asthma and 88 healthy controls. The authors reported the following:•There was no relationship between airway ACE2/TMPRSS2/furin expression with age or sex.•There was no difference in airway ACE2/TMPRSS2/furin expression between people with mild/moderate asthma versus severe asthma or compared to healthy controls (see Figure).•There were weak but highly significant positive and inverse correlations between ACE2 mRNA expression and molecular signatures of IL-17 and T~H~2 cytokine activity, respectively.

These data suggest that differences in ACE2, TMPRSS2, and furin epithelial and airway tissue gene expression are unlikely to confer enhanced COVID-19 pneumonia risk in patients with asthma of varying severity.Relative ACE2 mRNA expression in bronchial brushes in healthy, mild/moderate, and severe asthma.

Do allergy and asthma alter susceptibility to COVID-19? {#sec6}
=======================================================

Asthma and allergy are not highly represented as co-morbid conditions associated with COVID-19. In this issue, Kimura et al (p 80) investigated the effect of type 2 inflammation on the expression of molecules required for cell entry by SARS-CoV-2: ACE2 and TMPRSS2. The investigators found the following:•IL-13 significantly reduced ACE2 and increased TMPRSS2 expression ex vivo in airway epithelial cells (see Figure).•ACE2 expression was significantly reduced and TMPRSS2 expression was significantly increased in the nasal and airway epithelial cells in type 2 asthma and allergic rhinitis.•ACE2 expression was significantly negatively associated with type 2 cytokines, whereas TMPRSS2 expression was significantly positively associated with type 2 cytokines.

These observations provide a foundation to elucidate how type 2 inflammation may confer protection to COVID-19.IL-13 exposure reduces ACE2 and increases TMPRSS2 expression in airway epithelial cells.
